Increased sensitivity to warfarin in elderly Hispanics

被引:8
作者
Casner, PR [1 ]
Sandoval, E [1 ]
机构
[1] Texas Tech Univ, Hlth Sci Ctr, El Paso, TX 79905 USA
关键词
D O I
10.1177/00912700222011175
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
It has been suggested that aging enhances the pharmacologic effect of warfarin, but there is little information about the effects of warfarin in aging minority populations. The authors examine the response of an aging Hispanic population to warfarin. Charts in their anticoagulation clinic were retrospectively examined for the following information: age, sex, weight, duration of anticoagulant therapy; number of medical problems, number of medications, number of minor or major bleeding episodes, prothrombin time, warfarin dose, and international normalized ratio (INR). The dose-adjusted prothrombin time ratio (PTR) and dose-adjusted INR were calculated by dividing the PTR and INR by the mean warfarin dose. Four groups were compared by age: < 50, 50 to 59, 60 to 69, and greater than or equal to 70. A total of 243 charts were reviewed: 113 female, 130 male; 90% were Hispanic. The most common indication for anticoagulation was atrial fibrillation. Elderly patients had more medical problems (3.1 vs.2.4)and took more medications (3.4 vs. 2.4) than younger patients. The dose-adjusted PTR and dose-adjusted INR increased with aging (0.59 vs. 0.38 and 0.85 vs. 0.59, p < .05 ANOVA). In a multiple linear regression analysis, only age remained significantly associated with the anticoagulant effect. These results are consistent with previous reports on the effect of warfarin in aging patients and extend these data to the Hispanic population. (C) 2002 the American College of Clinical Pharmacology.
引用
收藏
页码:145 / 150
页数:6
相关论文
共 45 条
[1]   METHODOLOGICAL ISSUES IN HEALTH-CARE SURVEYS OF THE SPANISH HERITAGE POPULATION [J].
ADAY, LA ;
CHIU, GY ;
ANDERSEN, R .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1980, 70 (04) :367-374
[2]   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[3]  
BEIZER JL, 1994, PHYSL BASIS AGING GE, P279
[4]  
BOWLES SK, 1994, CLIN PHARMACOL THER, V55, P172
[5]   THE EFFECT OF AGE ON SERUM-ALBUMIN IN HEALTHY-MALES - REPORT FROM THE NORMATIVE AGING STUDY [J].
CAMPION, EW ;
DELABRY, LO ;
GLYNN, RJ .
JOURNALS OF GERONTOLOGY, 1988, 43 (01) :M18-M20
[6]   AGE AND WEIGHT AS DETERMINANTS OF WARFARIN REQUIREMENTS [J].
DOBRZANSKI, S ;
DUNCAN, SE ;
HARKISS, A ;
WARDLAW, A .
JOURNAL OF CLINICAL AND HOSPITAL PHARMACY, 1983, 8 (01) :75-77
[7]  
ECCLES J T, 1975, Age and Ageing, V4, P161, DOI 10.1093/ageing/4.3.161
[8]  
EDDINGTON ND, 1996, HDB PHARM AGING, P1
[9]  
*EP SERV, 1991, TRUE EP
[10]   Pharmacogenomics: Translating functional genomics into rational therapeutics [J].
Evans, WE ;
Relling, MV .
SCIENCE, 1999, 286 (5439) :487-491